US FDA declines to approve Rocket Pharma's immune disorder gene therapy-February 2024-www.financetom.com

US FDA declines to approve Rocket Pharma's immune disorder gene therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA declines to approve Rocket Pharma's immune disorder gene therapy

Jun 28, 2024 4:57 AM

June 28 (Reuters) - The U.S. Food and Drug

Administration has declined to approve Rocket Pharmaceuticals' ( RCKT )

gene therapy to treat a rare and severe pediatric

disorder that causes the immune system to malfunction, the

company said on Friday.

Previous page： Hong Kong-listed Samsonite plans dual listing in hunt for investors Next page： Meta's Instagram down for thousands, Downdetector shows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hong Kong-listed Samsonite plans dual listing in hunt for investors

Mar 21, 2024

(Reuters) -Luggage maker Samsonite International ( SMSOF ) on Friday said it plans to pursue a dual listing in addition to its listing on the Hong Kong Stock Exchange to increase the liquidity of its shares and reach investors in more markets. Samsonite ( SMSOF ) did not provide details of the exchanges it is considering for the second listing,...

Meta's Instagram down for thousands, Downdetector shows

Mar 21, 2024

March 21 (Reuters) - Meta Platforms's ( META ) Instagram was down for thousands of users on Thursday, according to outage tracking website Downdetector.com. ...

Oil eases on possible Gaza ceasefire, dollar strength

Mar 21, 2024

SINGAPORE (Reuters) -Oil prices slipped on Friday on the possibility of a nearing Gaza ceasefire that could ease geopolitical concerns in the Middle East, while a stronger dollar and faltering U.S. gasoline demand also weighed on prices. Brent crude futures fell 42 cents, or 0.5%, to $85.36 a barrel by 0203 GMT. U.S. crude futures shed 40 cents, or 0.5%,...

Ecopetrol's Reficar refinery awarded nearly 20% of McDermott common capital, company says

Mar 21, 2024

BOGOTA, March 21 (Reuters) - The Reficar oil refinery belonging to Colombia's Ecopetrol was awarded 19.9% of the common capital in infrastructure firm McDermott in preferential shares by a judge in Amsterdam, Ecopetrol said in a statement on Thursday. The refinery is located in the Colombian city of Cartagena. ...